Clinical trial · Observational
A Real-World Study of Second-line Therapies Among Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC) Patients
Real-World Evidence of Second-line Systematic Therapy With BRAF V600E Mutation-guided Dabrafenib + Trametinib or Mutation-agnostic Multi-targeted Tyrosine Kinase Inhibitors (MKIs) in Radioiodine-refractory Differentiated Thyroid Cancer (RAI-R DTC)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to assess patient characteristics and treatment patterns of second-line systematic therapies, including BRAF V600E mutation-guided dabrafenib plus trametinib (D+T) and MKIs, among Chinese adult patients with RAI-R DTC. This is a non-interventional study using secondary data derived from a real-world Electronic Health Record (rEHR) database in China.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Radioiodine-refractory Differentiated Thyroid Cancer | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- RAI-R DTC Cohort
- description
- Adult patients diagnosed with RAI-R DTC.
Primary outcomes (2)
- measure
- Proportion of Patients Receiving Second-line Systematic Therapy
- timeFrame
- Up to 6 years
- description
- Second-line systematic therapy includes lenvatinib, anlotinib, sorafenib, donafenib, and D+T.
- measure
- Duration of Second-line Systematic Therapy
- timeFrame
- Up to 6 years
- description
- Duration of therapy with lenvatinib, anlotinib, sorafenib, donafenib, and D+T.
Secondary outcomes (7)
- measure
- Proportion of Patients by Demographics and Clinical Characteristics
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion criteria: * Patients with a diagnosis of thyroid cancer. * Patients with a pathological confirmation of differentiated thyroid cancer (DTC). * Patients who initiated either MKI monotherapy (lenvatinib, sorafenib, anlotinib, donafenib, apatinib, sunitinib, cabozantinib, pralsetinib) or D+T combination therapy between January 1, 2019 and December 31, 2025 (or the data cutoff date). * Patients with no curative-intent thyroid cancer surgery within 3 months after initiation of systematic therapy. Exclusion criteria: • Patients participating in a blinded interventional clinical trial, or any open-label observational study involving D+T or MKI, during the study period. Other protocol-defined inclusion/exclusion criteria may apply.
References
Publications (0)
Data not yet available